Home / Products / Genome-edited Cells / PCCA Knockout Hep-G2 Cell Line

PCCA Knockout Hep-G2 Cell Line

Cat. No. ARG44024
Product Type:

In Stock Cell Lines

Species:

Homo sapiens (Human)

Tissue Source:

Liver

Growth Properties:

Adherent

In stock
Request a Quote

Short Description 🔒

The PCCA Knockout Hep-G2 Cell Line is a CRISPR/Cas9-edited knockout cell line that disrupts the PCCA gene in Hep-G2 hepatocellular carcinoma cells. This stable loss-of-function model eliminates the alpha subunit of propionyl-CoA carboxylase, preventing its assembly with the PCCB beta subunit and blocking the carboxylation of propionyl-CoA to methylmalonyl-CoA, thereby reducing succinyl-CoA anaplerosis. Suitable for modeling propionic acidemia and hepatic metabolic disorders, it enables investigation of mitochondrial dysfunction, drug toxicity, and metabolic flux using [13C]-propionate tracing, LC-MS metabolomics, and enzyme activity assays. The Hep-G2 background provides a wild-type p53 context for studying propionate-induced stress and therapeutic interventions.

Product Details
Cell Engineering
Immortalization
Culture Conditions
Quality Control
Disclaimer

Product Details

Product Type:
In Stock Cell Lines
Species:
Homo sapiens (Human)
Tissue Source:
Liver
Disease:
Hepatoblastoma
Morphology:
Epithelial-like
Growth Mode:
Adherent
Age:
15 years
Sex of Donor:
Male
Derived From Site:
In situ; Liver
Size/Quantity:
1 million
Shipping info:
Cryopreserved in vials and shipped on dry ice
Storage:
Liquid nitrogen (LN2)

Cell Engineering Information

Host Cell:
Hep-G2
Gene Name:
PCCA
Gene Identifier:
NCBI Gene ID 5095

Immortalization Information

No immortalization information available.

Culture Conditions

Temperature:
37°C
Atmosphere:
5% CO₂

Quality Control

Mycoplasma testing:
Negative for mycoplasma through PCR analysis
Sterility testing:
The bacterial, yeast, and fungi are not detected in these cells by daily monitor.

Disclaimer

Intended Use:
This product is intended for laboratory in vitro use only. It is not intended for diagnostic, therapeutic, or clinical applications.
Disclaimer:
Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability.
Usage:
By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use. This product is provided "AS IS".

Description 🔒

The PCCA Knockout Hep-G2 Cell Line is a CRISPR/Cas9-edited knockout cell line designed for targeted disruption of the PCCA gene in Hep-G2 hepatocellular carcinoma cells. This stable loss-of-function model enables investigation of propionyl-CoA carboxylase (PCC) alpha subunit function within a hepatic context. The engineered disruption abolishes catalytic conversion of propionyl-CoA to methylmalonyl-CoA, allowing study of metabolic pathway defects without overexpression artifacts. It is supplied as an adherent line, ready for standard culture protocols.

Hep-G2 is an adherent epithelial cell line derived from a well-differentiated hepatocellular carcinoma of a 15-year-old male, retaining wild-type p53 and numerous hepatic characteristics. This line serves as a foundational in vitro model for liver metabolism, toxicology, and oncogenesis research, exhibiting active expression of metabolic enzymes, transporters, and signaling networks relevant to hepatocyte physiology. The PCCA knockout in this background allows dissection of propionate catabolism within a human liver-derived system, facilitating comparison with primary hepatocytes and patient samples.

The PCCA gene encodes the alpha subunit of propionyl-CoA carboxylase, a mitochondrial biotin-dependent enzyme. It assembles with the PCCB beta subunit into the active heterododecamer. This complex catalyzes the carboxylation of propionyl-CoA to D-methylmalonyl-CoA, a pivotal step in degrading branched-chain amino acids and odd-chain fatty acids. Regulated by biotin availability and transcriptionally influenced by PPARA during lipid catabolism, PCCA-generated methylmalonyl-CoA is isomerized to succinyl-CoA by methylmalonyl-CoA mutase, feeding the TCA cycle. Knockout of PCCA disrupts this anaplerotic flux, causing accumulation of propionyl-CoA and odd-chain acyl intermediates, while depriving the TCA cycle of succinyl-CoA-derived carbons.

In the Hep-G2 background, PCCA knockout recapitulates propionic acidemia hallmarks, including impaired propionate metabolism and mitochondrial dysfunction. The hepatic context amplifies anaplerotic disruption, as TCA cycle function relies on amino acid?Cderived carbons. This model allows study of compensatory metabolic adaptations, such as glutaminolysis upregulation, and toxicity from propionate derivatives. The wild-type p53 status enables further evaluation of genotoxic stress under metabolite imbalance.

This knockout line is suited for modeling propionic acidemia-related metabolic acidosis, studying hepatic sensitivity to odd-chain fatty acid loads, and metabolic flux analysis using [13C]-propionate tracing. Researchers can combine LC-MS metabolomics, enzyme activity assays, Western blotting, and RT-qPCR to verify PCCA disruption and probe interconnected pathways like carbon metabolism. Cell viability assays under metabolic stress, such as high propionate or biotin depletion, aid therapeutic screening. For further technical details and custom solutions, please contact Ascent Research.